CELF4

Summary

CELF4 (CUGBP Elav-like family member 4, HGNC:14015) is a protein-coding gene on chromosome 18q12.2, encoding CUGBP Elav-like family member 4 (Q9BZC1). RNA-binding protein implicated in the regulation of pre-mRNA alternative splicing.

Members of the CELF/BRUNOL protein family contain two N-terminal RNA recognition motif (RRM) domains, one C-terminal RRM domain, and a divergent segment of 160-230 aa between the second and third RRM domains. Members of this protein family regulate pre-mRNA alternative splicing and may also be involved in mRNA editing, and translation. Multiple transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 56853 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Definitive, GenCC) — +1 more curated relationship
• GWAS associations: 36 (top 3% of genes corpus-wide)
• Clinical variants (ClinVar): 122 total — 1 pathogenic
• Regional missense constraint (gnomAD): 3 of 7 regions constrained (≈11% of expected missense variation)
• GTEx eGene: eQTL in 24 tissues, sQTL in 1 (q < 0.05)
• Dosage sensitivity (ClinGen): haploinsufficiency little evidence, triplosensitivity no evidence
• Constraint (gnomAD): pLI 0.84 (intermediate), LOEUF 0.55 (moderately constrained)
• MANE Select transcript: NM_020180

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14015
Approved symbol	CELF4
Name	CUGBP Elav-like family member 4
Location	18q12.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000101489
Ensembl biotype	protein_coding
OMIM	612679
Entrez	56853

Gene structure

Transcript identifiers

Ensembl transcripts: 52 — 46 protein_coding, 3 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay, 1 retained_intron

MANE Select: ENST00000420428

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 6, TSL 2: 5, TSL 3: 8, TSL 4: 1, TSL 5: 3

ENST00000420428, ENST00000334919, ENST00000361795, ENST00000586009, ENST00000587074, ENST00000587449, ENST00000587657, ENST00000587819, ENST00000587911, ENST00000587924, ENST00000588591, ENST00000588597, ENST00000589229, ENST00000589386, ENST00000590011, ENST00000590112, ENST00000591282, ENST00000591287, ENST00000591421, ENST00000593271, ENST00000601019, ENST00000601392, ENST00000603232, ENST00000899355, ENST00000899356, ENST00000899357, ENST00000899358, ENST00000899359, ENST00000899360, ENST00000899361, ENST00000899362, ENST00000899363, ENST00000899364, ENST00000899365, ENST00000931906, ENST00000970536, ENST00000970537, ENST00000970538, ENST00000970539, ENST00000970540, ENST00000970541, ENST00000970542, ENST00000970543, ENST00000970544, ENST00000970545, ENST00000970546, ENST00001009546, ENST00001009547, ENST00001009548, ENST00001009549, ENST00001098493, ENST00001131485

RefSeq mRNA: 70 — MANE Select: NM_020180 NM_001025087, NM_001025088, NM_001025089, NM_001330603, NM_001353695, NM_001353696, NM_001353697, NM_001353698, NM_001353699, NM_001353700, NM_001353702, NM_001353703, NM_001353705, NM_001353706, NM_001353707, NM_001353708, NM_001353709, NM_001353710, NM_001353711, NM_001353712, NM_001353713, NM_001353714, NM_001353715, NM_001353716, NM_001353717, NM_001353718, NM_001353719, NM_001353720, NM_001353721, NM_001353722, NM_001353723, NM_001353724, NM_001353725, NM_001353726, NM_001353727, NM_001353728, NM_001353729, NM_001353730, NM_001353731, NM_001353732, NM_001353733, NM_001353734, NM_001353735, NM_001353736, NM_001353737, NM_001353738, NM_001353739, NM_001353740, NM_001353741, NM_001353742, NM_001353743, NM_001353744, NM_001353745, NM_001353746, NM_001353747, NM_001353748, NM_001353749, NM_001353750, NM_001353751, NM_001353752, NM_001353753, NM_001353754, NM_001353755, NM_001353756, NM_001353757, NM_001353758, NM_001353759, NM_001353760, NM_001353761, NM_020180

CCDS: CCDS32818, CCDS45856, CCDS45857, CCDS45858, CCDS82250

Canonical transcript exons

ENST00000420428 — 13 exons

Exon	Start	End
ENSE00002725604	37565356	37565798
ENSE00003469310	37485525	37485607
ENSE00003475741	37266533	37266598
ENSE00003485344	37259181	37259264
ENSE00003506464	37270768	37270917
ENSE00003569898	37273016	37273163
ENSE00003632296	37264674	37264757
ENSE00003658067	37253767	37253938
ENSE00003847371	37243040	37245197
ENSE00003889351	37275115	37275243
ENSE00003889387	37274311	37274454
ENSE00003891907	37321803	37321881
ENSE00003892208	37274805	37274884

Expression profiles

Bgee: expression breadth ubiquitous, 183 present calls, max score 97.29.

FANTOM5 (CAGE): breadth broad, TPM avg 5.0549 / max 1047.8138, expressed in 310 samples.

Highest expression (Bgee): cerebellar cortex, cerebellar hemisphere, Brodmann (1909) area 9, hemisphere of cerebellum, primary visual cortex.

Genetic regulation across tissues (GTEx eQTL / sQTL)

CELF4 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 24 tissues and its splicing (sQTL) in 1 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 25 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Nerve Tibial	eqtl	2.7e-29	-0.67	18:36949475:A:C
Testis	sqtl	2.6e-22	+0.96	18:37322162:T:G
Skin Sun Exposed Lower leg	eqtl	2.0e-20	-0.60	18:36995714:G:T
Skin Not Sun Exposed Suprapubic	eqtl	4.0e-13	-0.54	18:36949475:A:C
Esophagus Mucosa	eqtl	2.0e-12	-0.59	18:36879775:G:A
Thyroid	eqtl	4.5e-12	+0.46	18:36923067:C:T
Artery Tibial	eqtl	2.0e-10	-0.45	18:37103271:G:T
Breast Mammary Tissue	eqtl	4.7e-08	-0.42	18:36848399:A:T
Adipose Subcutaneous	eqtl	8.5e-08	-0.38	18:37229747:G:A
Esophagus Muscularis	eqtl	3.7e-06	-0.21	18:37162663:C:T
Colon Transverse	eqtl	5.1e-05	-0.15	18:37252704:G:A
Artery Aorta	eqtl	6.2e-05	-0.36	18:37258244:C:T
Muscle Skeletal	eqtl	3.4e-04	-0.29	18:37216697:G:C
Small Intestine Terminal Ileum	eqtl	5.4e-04	-0.36	18:37166595:T:G
Brain Hippocampus	eqtl	6.9e-04	+0.37	18:37707164:A:G
Ovary	eqtl	1.3e-03	-0.44	18:37192536:A:G
Brain Cortex	eqtl	1.4e-03	-0.15	18:37251003:A:G
Artery Coronary	eqtl	1.4e-03	-0.48	18:37261740:G:T
Vagina	eqtl	1.9e-03	-0.43	18:37223202:A:G
Lung	eqtl	3.2e-03	-0.28	18:37252704:G:A

FANTOM5 promoters

showing 10 of 11 alternative TSS:

Promoter ID	TPM avg	Samples expressed
171723	2.6440	137
171722	0.7488	103
171705	0.3728	137
171725	0.3664	104
171720	0.2990	88
171712	0.1781	92
171713	0.1676	61
171721	0.1316	60
171724	0.0657	39
171718	0.0429	31

Top tissues by expression

showing 100 of 252 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cerebellar cortex	UBERON:0002129	97.29	gold quality
cerebellar hemisphere	UBERON:0002245	97.28	gold quality
Brodmann (1909) area 9	UBERON:0013540	97.15	gold quality
right hemisphere of cerebellum	UBERON:0014890	97.08	gold quality
primary visual cortex	UBERON:0002436	97.01	gold quality
cerebellum	UBERON:0002037	96.93	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	96.66	gold quality
Brodmann (1909) area 23	UBERON:0013554	96.55	gold quality
right frontal lobe	UBERON:0002810	96.50	gold quality
anterior cingulate cortex	UBERON:0009835	96.40	gold quality
prefrontal cortex	UBERON:0000451	96.35	gold quality
frontal cortex	UBERON:0001870	96.21	gold quality
neocortex	UBERON:0001950	95.87	gold quality
superior frontal gyrus	UBERON:0002661	95.83	gold quality
occipital lobe	UBERON:0002021	95.66	gold quality
nucleus accumbens	UBERON:0001882	95.58	gold quality
cerebral cortex	UBERON:0000956	95.43	gold quality
entorhinal cortex	UBERON:0002728	95.33	gold quality
amygdala	UBERON:0001876	95.29	gold quality
hypothalamus	UBERON:0001898	95.29	gold quality
temporal lobe	UBERON:0001871	95.16	gold quality
cerebellar vermis	UBERON:0004720	95.14	gold quality
postcentral gyrus	UBERON:0002581	94.60	gold quality
substantia nigra pars compacta	UBERON:0001965	94.53	gold quality
parietal lobe	UBERON:0001872	94.46	gold quality
Brodmann (1909) area 46	UBERON:0006483	94.39	gold quality
middle temporal gyrus	UBERON:0002771	94.36	gold quality
brain	UBERON:0000955	94.01	gold quality
forebrain	UBERON:0001890	93.99	gold quality
Ammon’s horn	UBERON:0001954	93.77	gold quality
caudate nucleus	UBERON:0001873	93.07	gold quality
cortical plate	UBERON:0005343	92.90	gold quality
putamen	UBERON:0001874	92.85	gold quality
substantia nigra pars reticulata	UBERON:0001966	92.75	gold quality
pons	UBERON:0000988	92.21	gold quality
superior vestibular nucleus	UBERON:0007227	91.67	gold quality
ventral tegmental area	UBERON:0002691	90.53	gold quality
adenohypophysis	UBERON:0002196	90.46	gold quality
lateral nuclear group of thalamus	UBERON:0002736	90.30	gold quality
substantia nigra	UBERON:0002038	90.18	gold quality
midbrain	UBERON:0001891	90.08	gold quality
pituitary gland	UBERON:0000007	90.03	gold quality
endothelial cell	CL:0000115	87.77	gold quality
medulla oblongata	UBERON:0001896	87.14	gold quality
buccal mucosa cell	CL:0002336	86.19	gold quality
dorsal root ganglion	UBERON:0000044	83.82	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.53	gold quality
ganglionic eminence	UBERON:0004023	80.11	gold quality
lateral globus pallidus	UBERON:0002476	79.06	gold quality
islet of Langerhans	UBERON:0000006	78.80	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	78.74	gold quality
spinal cord	UBERON:0002240	78.09	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	77.77	gold quality
dorsal plus ventral thalamus	UBERON:0001897	77.40	gold quality
pancreatic ductal cell	CL:0002079	76.02	silver quality
sural nerve	UBERON:0015488	75.86	gold quality
ventricular zone	UBERON:0003053	74.06	gold quality
globus pallidus	UBERON:0001875	73.17	gold quality
medial globus pallidus	UBERON:0002477	72.32	gold quality
pancreas	UBERON:0001264	71.72	gold quality
body of pancreas	UBERON:0001150	69.40	gold quality
adult organism	UBERON:0007023	69.35	silver quality
left testis	UBERON:0004533	69.20	gold quality
right testis	UBERON:0004534	68.57	gold quality
testis	UBERON:0000473	67.66	gold quality
corpus callosum	UBERON:0002336	66.95	gold quality
subthalamic nucleus	UBERON:0001906	66.34	gold quality
body of stomach	UBERON:0001161	66.21	gold quality
gall bladder	UBERON:0002110	66.10	gold quality
trigeminal ganglion	UBERON:0001675	65.94	gold quality
muscle layer of sigmoid colon	UBERON:0035805	65.34	gold quality
stomach	UBERON:0000945	64.39	gold quality
tendon of biceps brachii	UBERON:0008188	64.05	gold quality
left ovary	UBERON:0002119	63.50	gold quality
colonic epithelium	UBERON:0000397	63.44	gold quality
vermiform appendix	UBERON:0001154	62.77	gold quality
anatomical system	UBERON:0000467	61.77	gold quality
parotid gland	UBERON:0001831	61.71	gold quality
fundus of stomach	UBERON:0001160	61.67	gold quality
hindlimb stylopod muscle	UBERON:0004252	61.65	gold quality
apex of heart	UBERON:0002098	61.59	gold quality
multicellular organism	UBERON:0000468	61.42	gold quality
right adrenal gland	UBERON:0001233	61.42	gold quality
material anatomical entity	UBERON:0000465	61.40	gold quality
adrenal gland	UBERON:0002369	61.17	gold quality
tibialis anterior	UBERON:0001385	60.99	silver quality
cortex of kidney	UBERON:0001225	60.70	gold quality
right ovary	UBERON:0002118	60.48	gold quality
left adrenal gland cortex	UBERON:0035825	60.43	gold quality
left adrenal gland	UBERON:0001234	60.03	gold quality
right atrium auricular region	UBERON:0006631	59.63	gold quality
ovary	UBERON:0000992	59.18	gold quality
cardiac atrium	UBERON:0002081	59.05	gold quality
adrenal cortex	UBERON:0001235	59.00	gold quality
oviduct epithelium	UBERON:0004804	58.79	silver quality
lower esophagus muscularis layer	UBERON:0035833	58.62	gold quality
lower esophagus	UBERON:0013473	58.48	gold quality
adrenal tissue	UBERON:0018303	58.48	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	58.06	gold quality
metanephros cortex	UBERON:0010533	57.89	gold quality

Single-cell (SCXA)

Detected in 10 experiment(s), a significant marker in 10.

Experiment	Marker?	Max mean expression
E-MTAB-7316	yes	954.02
E-MTAB-11121	yes	690.43
E-HCAD-5	yes	519.48
E-GEOD-75140	yes	90.69
E-HCAD-35	yes	63.73
E-HCAD-25	yes	36.94
E-GEOD-93593	yes	16.57
E-GEOD-137537	yes	11.04
E-GEOD-84465	yes	7.06
E-ANND-3	yes	4.07

HPA expression

RNA tissue specificity: Tissue enhanced

showing 60 of 75 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Postcentral gyrus	tissue	235.2
Frontal cortex	tissue	230.9
Hippocampus	tissue	147.3	low
Caudate putamen	tissue	146.4
Locus coeruleus	tissue	143.4
Nucleus accumbens	tissue	94.2
Prefrontal cortex	tissue	92.4
Cerebral cortex	tissue	92.4	medium
Cerebellum	tissue	92.0	low
Basal ganglia	tissue	87.0	medium
Hippocampal formation	tissue	85.5
Motor cortex	tissue	85.4
Olfactory bulb	tissue	84.7
Retrosplenial cortex	tissue	79.6
Retrosplenial and cingulate cortex	tissue	79.4
Insular cortex	tissue	78.8
Entorhinal cortex	tissue	78.3
Putamen	tissue	77.6
Ventral forebrain	tissue	74.5
Occipital cortex	tissue	72.4
Somatosensory cortex	tissue	72.2
Amygdala	tissue	71.0
Temporal cortex	tissue	70.3
Septum	tissue	69.3
Pons	tissue	67.5
Hypothalamus	tissue	64.7
Thalamus	tissue	61.5
Midbrain	tissue	53.6
Substantia nigra	tissue	52.9
Periaqueductal gray	tissue	46.6
Superior colliculi	tissue	40.4
Medulla oblongata	tissue	29.1
Pituitary gland	tissue	26.9
Retina	tissue	19.8
Spinal cord	tissue	18.2
Corpus callosum	tissue	17.6
Choroid plexus	tissue	13.5
Adrenal gland	tissue	10.8	not detected
Skeletal muscle	tissue	10.2	not detected
Pancreas	tissue	3.7	not detected
Testis	tissue	3.4	not detected
Salivary gland	tissue	1.6	not detected
Thyroid gland	tissue	1.4	not detected
Skin 1	tissue	1.2	not detected
Small intestine	tissue	1.2	not detected
Gallbladder	tissue	1.2	not detected
Heart muscle	tissue	1.0	not detected
Spleen	tissue	1.0	not detected
Appendix	tissue	1.0	not detected
Lymph node	tissue	0.8	not detected
Stomach 1	tissue	0.8	not detected
Placenta	tissue	0.8	not detected
Ovary	tissue	0.7	not detected
Colon	tissue	0.7	not detected
Duodenum	tissue	0.7	not detected
Prostate	tissue	0.7	not detected
Adipose tissue	tissue	0.6	not detected
Kidney	tissue	0.6	not detected
Esophagus	tissue	0.5	not detected
Smooth muscle	tissue	0.5	not detected

Brain sub-regions (HPA Brain Atlas): detected in 189; highest nTPM — Olfactory area (212.2), Olfactory tubercle (208.0), Stria terminalis, bed nucleus (205.2), Posterior insular cortex (204.7), Perirhinal gyrus (191.2).

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

Targeting CELF4 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 145 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-3065-5P	99.97	71.56	3281

Functional genomics

gnomAD constraint: pLI 0.836, LOEUF 0.546, missense Z 2.88 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD)

ENST00000420428 splits into 7 regions with different missense tolerance; 3 are missense-constrained (≈11% of the expected missense variation). Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD

Region (GRCh38)	Missense obs / exp	o/e	Constrained
18:37,253,814–37,274,378	256 / 340.8	0.75	no
18:37,274,379–37,274,435	6 / 29.6	0.20	yes (p 1.4e-05)
18:37,274,436–37,275,201	56 / 92.0	0.61	no
18:37,275,202–37,321,808	1 / 18.6	0.05	yes (p 4.5e-05)
18:37,321,809–37,565,429	63 / 110.6	0.57	no
18:37,565,430–37,565,493	4 / 27.8	0.14	yes (p 6.5e-06)
18:37,565,494–37,565,641	70 / 69.5	1.01	no
ClinGen dosage: haploinsufficiency 1 (little evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 6)

• Determination of CELF4 protein domains required for RNA splicing. (PMID:14973222)
• validated occurrence of an unusual TG 3’ splice site in intron 6 (PMID:17672918)
• Authors report a modifying effect of a polymorphism of CELF4 on the dose-dependent association between anthracyclines and cardiomyopathy, which possibly occurs through a pathway that involves the expression of abnormally spliced TNNT2 variants. (PMID:26811534)
• The present study refines the molecular and neuropsychiatric phenotype associated with 18q12.2 deletion leading to CELF4 haploinsufficiency and provides evidence for a role for CELF4 in brain development and autism spectrum disorders. (PMID:28407444)
• An intronic variant in the CELF4 gene is associated with risk for colorectal cancer. (PMID:33930674)
• Celf4 controls mRNA translation underlying synaptic development in the prenatal mammalian neocortex. (PMID:37758766)

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
danio_rerio	celf4	ENSDARG00000070045
mus_musculus	Celf4	ENSMUSG00000024268
rattus_norvegicus	Celf4	ENSRNOG00000014503
drosophila_melanogaster	bru1	FBGN0000114
drosophila_melanogaster	Pof	FBGN0035047
drosophila_melanogaster	bru2	FBGN0262475
caenorhabditis_elegans		WBGENE00017135
caenorhabditis_elegans		WBGENE00017140
caenorhabditis_elegans		WBGENE00020354

Paralogs (6): CELF2 (ENSG00000048740), RBM28 (ENSG00000106344), CELF6 (ENSG00000140488), CELF1 (ENSG00000149187), CELF3 (ENSG00000159409), CELF5 (ENSG00000161082)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:1932407) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 29 distinct phenotype terms.

Mouse phenotype (MP)	Records
decreased body size	2
seizures	2
absence seizures	2
tonic-clonic seizures	2
increased susceptibility to induction of seizure by inducing agent	2
decreased circulating calcium level	1
convulsive seizures	1
increased body weight	1
hyperactivity	1
abnormal seizure response to electrical stimulation	1
increased circulating insulin level	1
premature death	1
abnormal bile duct morphology	1
abnormal eye muscle morphology	1
fetal growth retardation	1
abnormal miniature excitatory postsynaptic currents	1
decreased circulating cholesterol level	1
impaired glucose tolerance	1
increased susceptibility to weight gain	1
abnormal spike wave discharge	1
postnatal lethality, incomplete penetrance	1
neonatal lethality, incomplete penetrance	1
preweaning lethality, complete penetrance	1
dual inferior vena cava	1
decreased susceptibility to induction of seizure by inducing agent	1

+4 more (showing top 25).

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Pongo abelii	Q5NVC8	100.0%	Diamond
Gallus gallus	Q7T2T1	99.8%	Diamond
Oryza sativa Indica Group	B8BCZ8	99.5%	Diamond
Oryza sativa Japonica Group	Q6K271	99.5%	Diamond
Bos taurus	Q08E07	98.3%	Diamond
Macaca fascicularis	Q4R535	97.5%	Diamond
Xenopus tropicalis	A4IIM2	96.8%	Diamond
Xenopus laevis	Q7ZXE2	96.8%	Diamond
Canis lupus familiaris	Q9XSR3	93.8%	Diamond
Arabidopsis thaliana	Q9ZW36	92.1%	Diamond
Musca domestica	O17310	90.6%	Diamond
Chrysomya rufifacies	O97018	90.6%	Diamond
Plasmodium falciparum	P13824	65.7%	Diamond
Saccharomyces cerevisiae S288C	Q00916	46.2%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
SNORA111	snoRNA	106635546
KIAA1328	protein-coding	57536
TPGS2	protein-coding	25941
FHOD3	protein-coding	80206
MIR4318	ncRNA	100422857

Protein

Protein identifiers

CUGBP Elav-like family member 4 — Q9BZC1 (reviewed: Q9BZC1)

Alternative names: Bruno-like protein 4, CUG-BP- and ETR-3-like factor 4, RNA-binding protein BRUNOL-4

All UniProt accessions (14): A0A0A0MTT3, A0A0C4DGR1, B4DHA8, Q9BZC1, K7EJ26, K7EJD7, K7EJK3, K7EJW4, K7ENR2, K7EPX2, K7EQ97, K7ERH1, M0QY66, M0R137

UniProt curated annotations — full annotation on UniProt →

Function. RNA-binding protein implicated in the regulation of pre-mRNA alternative splicing. Mediates exon inclusion and/or exclusion in pre-mRNA that are subject to tissue-specific and developmentally regulated alternative splicing. Specifically activates exon 5 inclusion of cardiac isoforms of TNNT2 during heart remodeling at the juvenile to adult transition. Promotes exclusion of both the smooth muscle (SM) and non-muscle (NM) exons in actinin pre-mRNAs. Activates the splicing of MAPT/Tau exon 10. Binds to muscle-specific splicing enhancer (MSE) intronic sites flanking the alternative exon 5 of TNNT2 pre-mRNA.

Subcellular location. Nucleus. Cytoplasm.

Tissue specificity. Ubiquitous. Strongly expressed in the cerebellum, hippocampus, amygdala, temporal and frontal cortex and frontal lobes.

Similarity. Belongs to the CELF/BRUNOL family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q9BZC1-1	1	yes
Q9BZC1-2	2
Q9BZC1-3	3
Q9BZC1-4	4
Q9BZC1-5	5

RefSeq proteins (70): NP_001020258, NP_001020259, NP_001020260, NP_001317532, NP_001340624, NP_001340625, NP_001340626, NP_001340627, NP_001340628, NP_001340629, NP_001340631, NP_001340632, NP_001340634, NP_001340635, NP_001340636, NP_001340637, NP_001340638, NP_001340639, NP_001340640, NP_001340641, NP_001340642, NP_001340643, NP_001340644, NP_001340645, NP_001340646, NP_001340647, NP_001340648, NP_001340649, NP_001340650, NP_001340651, NP_001340652, NP_001340653, NP_001340654, NP_001340655, NP_001340656, NP_001340657, NP_001340658, NP_001340659, NP_001340660, NP_001340661, NP_001340662, NP_001340663, NP_001340664, NP_001340665, NP_001340666, NP_001340667, NP_001340668, NP_001340669, NP_001340670, NP_001340671, NP_001340672, NP_001340673, NP_001340674, NP_001340675, NP_001340676, NP_001340677, NP_001340678, NP_001340679, NP_001340680, NP_001340681, NP_001340682, NP_001340683, NP_001340684, NP_001340685, NP_001340686, NP_001340687, NP_001340688, NP_001340689, NP_001340690, NP_064565* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000504	RRM_dom	Domain
IPR012677	Nucleotide-bd_a/b_plait_sf	Homologous_superfamily
IPR034648	CELF3/4/5/6_RRM1	Domain
IPR035979	RBD_domain_sf	Homologous_superfamily

Pfam: PF00076

UniProt features (35 total): strand 9, splice variant 5, sequence conflict 4, helix 4, region of interest 4, domain 3, turn 2, compositionally biased region 2, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

2 structures by resolution:

PDB	Title	Method	Resolution (Å)
2DGP	Solution structure of the N-terminal RNA binding domain in Bruno-like 4 RNA-binding …	SOLUTION NMR
2DNK	Solution structure of RNA binding domain in Bruno-like 4 RNA binding protein	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BZC1-F1	62.70	0.23

Human Protein Atlas

Protein class: Predicted intracellular proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): nucleoplasm

Antibody reliability (HPA): IH enhanced · IF supported

Function

Pathways and Gene Ontology

Reactome pathways

0 curated (TAS) of 0; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

MSigDB gene sets: 278 (showing top): GGGACCA_MIR133A_MIR133B, RNGTGGGC_UNKNOWN, RRAGTTGT_UNKNOWN, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, HNF3ALPHA_Q6, GOBP_POSITIVE_REGULATION_OF_RNA_SPLICING, GOBP_POSITIVE_REGULATION_OF_MRNA_PROCESSING, GCANCTGNY_MYOD_Q6, GOBP_ALTERNATIVE_MRNA_SPLICING_VIA_SPLICEOSOME, GOBP_NEGATIVE_REGULATION_OF_RNA_SPLICING, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, MEF2_02, GGGTGGRR_PAX4_03, GCGCTTT_MIR518B_MIR518C_MIR518D

GO Biological Process (10): alternative mRNA splicing, via spliceosome (GO:0000380), regulation of alternative mRNA splicing, via spliceosome (GO:0000381), mRNA splice site recognition (GO:0006376), germ cell development (GO:0007281), embryo development ending in birth or egg hatching (GO:0009792), positive regulation of mRNA splicing, via spliceosome (GO:0048026), mRNA splicing, via spliceosome (GO:0000398), mRNA processing (GO:0006397), RNA splicing (GO:0008380), negative regulation of translation (GO:0017148)

GO Molecular Function (7): mRNA regulatory element binding translation repressor activity (GO:0000900), mRNA binding (GO:0003729), pre-mRNA binding (GO:0036002), BRE binding (GO:0042835), nucleic acid binding (GO:0003676), RNA binding (GO:0003723), protein binding (GO:0005515)

GO Cellular Component (4): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), ribonucleoprotein complex (GO:1990904)

GO top-level categories

31 GO namespaces:

Category	Terms
RNA binding	3
mRNA splicing, via spliceosome	2
regulation of mRNA splicing, via spliceosome	2
RNA processing	2
binding	2
cellular anatomical structure	2
alternative mRNA splicing, via spliceosome	1
spliceosomal complex assembly	1
protein-RNA complex assembly	1
developmental process involved in reproduction	1
gamete generation	1
cellular process involved in reproduction in multicellular organism	1
cell development	1
embryo development	1
animal gross anatomical part developmental process	1
positive regulation of RNA splicing	1
positive regulation of mRNA processing	1
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	1
mRNA processing	1
mRNA metabolic process	1
translation	1
regulation of translation	1
negative regulation of gene expression	1
negative regulation of protein metabolic process	1
mRNA binding	1
translation repressor activity	1
nucleic acid binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
protein-containing complex	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 6 of 21 annotations. The rest are phylogenetic / computational / electronic (IEA).

6 experimentally-supported GO terms:

GO term	NS	Evidence
alternative mRNA splicing, via spliceosome	BP	direct assay
positive regulation of mRNA splicing, via spliceosome	BP	direct assay
regulation of alternative mRNA splicing, via spliceosome	BP	direct assay
nucleoplasm	CC	direct assay
nucleus	CC	direct assay
pre-mRNA binding	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 964 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CELF4	CEBPD	P49716	881
CELF4	BICD1	Q96G01	837
CELF4	DDX11	Q96FC9	759
CELF4	TNNT2	P45379	698
CELF4	PLEKHB2	Q96CS7	592
CELF4	RBFOX1	Q9NWB1	532
CELF4	MBNL2	Q5VZF2	515
CELF4	MBNL1	Q9NR56	488
CELF4	MBNL3	Q9NUK0	485
CELF4	SRSF6	Q13247	477
CELF4	SRSF4	Q08170	455
CELF4	RBFOX2	O43251	446
CELF4	CLCN1	P35523	443
CELF4	SRSF9	Q13242	435
CELF4	SLC28A3	Q9HAS3	419

IntAct

BioGRID (14 interactions; top human partners by supporting records): APP (Reconstituted Complex), AUP1 (Affinity Capture-MS), LPCAT1 (Affinity Capture-MS), LYST (Two-hybrid), MSI2 (Affinity Capture-MS), PCBP3 (Two-hybrid), POLI (Reconstituted Complex), PRR20A (Two-hybrid), PRR20B (Two-hybrid), PRR20C (Two-hybrid), PRR20D (Two-hybrid), PRR20E (Two-hybrid), RBPMS2 (Two-hybrid), TIAL1 (Two-hybrid)

SIGNOR signaling

2 signaling interactions:

A	Effect	B	Mechanism
CELF4	“up-regulates quantity”	TNNT2	“post transcriptional regulation”
CELF4	up-regulates	Excitatory_synaptic_transmission

Disease & clinical

Genetic variants

Variant evidence for CELF4: 122 ClinVar records (1 pathogenic / likely pathogenic); 1 PharmGKB clinical annotation; 36 GWAS associations. Per-variant detail is on Sugi Variant.

ClinVar

122 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	89
Likely benign	17
Benign	6

Top pathogenic / likely-pathogenic (1)

Showing all 1 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
3774946	NM_020180.4(CELF4):c.226G>T (p.Glu76Ter)	Pathogenic	criteria provided, single submitter	1

Per-variant reference — Sugi Variant

Explore CELF4’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 35 predictions of 1,678):

Position(s)	Effect	Δscore	Sites
18:37253765–37253766	donor_loss	1.0000	4
18:37264811	acceptor_gain	1.0000
18:37270930	acceptor_gain	1.0000
18:37273014–37273015	donor_loss	1.0000	5
18:37273164–37273165	acceptor_loss	1.0000	5
18:37273171	acceptor_gain	1.0000
18:37274309–37274310	donor_loss	1.0000	4
18:37274803–37274804	donor_loss	1.0000	3
18:37485608–37485609	acceptor_loss	1.0000	6
18:37253939–37253940	acceptor_loss	0.9900	5

AlphaMissense

1,948 missense substitutions predicted likely pathogenic (of 3,235 scored), across 424 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M158	9	0.998	1.000
M124	9	0.994	1.000
M462	9	0.915	0.997
M440	9	0.827	0.990
F196	8	1.000	1.000
F57	8	0.999	1.000
D88	8	0.999	1.000
F99	8	0.999	1.000
H116	8	0.999	1.000
F155	8	0.999	1.000
D231	8	0.998	1.000
F74	8	0.997	1.000
H94	8	0.997	1.000
H427	8	0.997	1.000
F441	8	0.997	1.000
F172	8	0.995	0.999
F424	8	0.994	1.000
D434	8	0.990	0.999
S191	8	0.985	1.000
H213	8	0.979	0.997

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

1 prognostic cancer types:

Cancer	Prognostic	p-value
Uterine Corpus Endometrial Carcinoma (TCGA)	unfavorable	1.68e-05

Disease associations

OMIM: gene MIM:612679 | disease phenotypes:

GenCC curated gene-disease

2 curated gene-disease records:

Disease	Classification	Inheritance	Records
neurodevelopmental disorder	Definitive	Autosomal dominant
complex neurodevelopmental disorder	Limited	Autosomal dominant

Genomics England panels (PanelApp)

Clinical diagnostic gene panels including this gene (7 panels, 1 green/diagnostic-grade). Confidence: green = diagnostic, amber = moderate.

7 panels:

Panel	Rating
DDG2P	green
Early onset or syndromic epilepsy	amber
Hypotonic infant	amber
Intellectual disability	amber
Leukodystrophy, childhood onset	amber
Paediatric disorders	amber
Unexplained death in infancy and sudden unexplained death in childhood	amber

Mondo (2): complex neurodevelopmental disorder (MONDO:0100038), neurodevelopmental disorder (MONDO:0700092)

GWAS associations

showing 30 of 36 associations:

Study	Trait	p-value
GCST011494_24	Daytime nap	3e-28
GCST006940_127	Neurociticism	4e-21
GCST006951_27	Feeling hurt	4e-16
GCST008595_68	Cognitive ability, years of educational attainment or schizophrenia (pleiotropy)	6e-15
GCST009524_4	Household income (MTAG)	4e-14
GCST006947_40	Feeling fed-up	4e-13
GCST007709_99	General factor of neuroticism	4e-13
GCST007709_100	General factor of neuroticism	6e-13
GCST90000514_13	Gastroesophageal reflux disease	1e-12
GCST006944_68	Experiencing mood swings	9e-12
GCST006946_18	Worry too long after an embarrassing experience	4e-11
GCST006943_49	Feeling miserable	2e-10
GCST006945_17	Feeling guilty	4e-10
GCST008357_26	Mood instability	7e-10
GCST009524_248	Household income (MTAG)	1e-9
GCST009523_63	Household income	2e-9
GCST009524_220	Household income (MTAG)	3e-9
GCST007576_227	Chronotype	4e-9
GCST003770_35	Neuroticism	6e-9
GCST012355_41	Depression	7e-9
GCST003447_9	Neuroticism	1e-8
GCST007709_130	General factor of neuroticism	1e-8
GCST010002_363	Refractive error	1e-8
GCST003770_64	Neuroticism	2e-8
GCST009523_62	Household income	2e-8
GCST003264_52	Post bronchodilator FEV1/FVC ratio	4e-8
GCST005835_7	Remission after SSRI treatment in MDD or neuroticism	4e-8
GCST002598_46	Educational attainment	3e-7
GCST003262_735	Post bronchodilator FEV1	4e-7
GCST002337_139	Amyotrophic lateral sclerosis (sporadic)	2e-6

EFO canonical traits (from GWAS)

17 canonical traits:

EFO ID	Trait name
EFO:0005427	social communication impairment
EFO:0004784	self reported educational attainment
EFO:0004314	forced expiratory volume
EFO:0004713	FEV/FVC ratio
EFO:0007660	neuroticism measurement
EFO:0005658	response to selective serotonin reuptake inhibitor
EFO:0009598	feeling miserable measurement
EFO:0008475	mood instability measurement
EFO:0009595	guilt measurement
EFO:0009589	worry measurement
EFO:0009588	feeling “fed-up” measurement
EFO:0009599	feeling emotionally hurt measurement
EFO:0008328	chronotype measurement
EFO:0004337	intelligence
EFO:0009695	household income
EFO:0007828	daytime rest measurement
EFO:0004612	high density lipoprotein cholesterol measurement

MeSH disease descriptors

1 disease descriptors:

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (CPIC guideline: no)

PharmGKB clinical annotations

1 annotations by evidence level (1 strongest → 4):

Variant	Association	Level	Drugs	Phenotypes
rs4799915	Toxicity	3	iloperidone	Acquired Long QT Syndrome (aLQTS)

PharmGKB variants

1 variants:

Variant	Genes	Level	Score	#Clin annots	Drugs
rs4799915	CELF4	3	0.00	1	iloperidone

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects expression, increases methylation, affects cotreatment	6
Acetaminophen	decreases expression	2
Benzo(a)pyrene	decreases methylation, affects methylation	2
Aflatoxin B1	decreases methylation, increases methylation	2
methylmercuric chloride	increases expression	1
propionaldehyde	increases expression	1
bisphenol A	decreases methylation	1
arsenite	increases methylation	1
butyraldehyde	increases expression	1
benzo(e)pyrene	affects methylation	1
aflatoxin B2	affects methylation	1
S-(1,2-dichlorovinyl)cysteine	decreases expression	1
pentanal	increases expression	1
CGP 52608	affects binding, increases reaction	1
entinostat	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol S	affects cotreatment, decreases methylation, affects methylation	1
Fulvestrant	affects cotreatment, decreases methylation	1
Vorinostat	decreases expression	1
Aldehydes	increases expression	1
Arsenic	affects methylation	1
Methapyrilene	affects methylation	1
Phthalic Acids	decreases methylation	1
Rotenone	decreases expression	1
Silicon Dioxide	decreases expression	1
Smoke	increases expression	1
Triclosan	increases expression	1
Antirheumatic Agents	increases expression	1

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 217 trials:

NCT	Phase	Status	Title
NCT04586348	Phase 4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	Phase 4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	Phase 3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	Phase 3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	Phase 3	RECRUITING	Reducing Missed Appointments
NCT07377032	Phase 3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	Phase 2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	Phase 2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	Phase 2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	Phase 1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	Phase 1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	Phase 1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT03600649	Phase 1	UNKNOWN	Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
NCT06310681	Not specified	COMPLETED	Pilot Testing of a Co-adapted Group Programme for Parents/Carers of Children With Complex Neurodisability
NCT07303049	Not specified	NOT_YET_RECRUITING	Cognitive Benefit of Intensive Rehabilitation Using Rhythmic Music Training in Children With Complex Neurodevelopmental Disorder
NCT01783041	Phase 2/3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	Phase 2/3	COMPLETED	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	Early Phase 1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	COMPLETED	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice
NCT03381027	Not specified	COMPLETED	BABY SMART (Study of Massage Therapy, Sleep And neurodevelopMenT)
NCT03388294	Not specified	COMPLETED	Evaluation of a Novel Intervention for Infants At Risk for Neurodevelopmental Disorders
NCT03410810	Not specified	UNKNOWN	Childhood Outcomes of Preterm Brain Abnormalities
NCT03492060	Not specified	RECRUITING	Longitudinal Study of Neurogenetic Disorders
NCT03577756	Not specified	COMPLETED	Neurodevelopmental Assessment of Infants With Cystic Fibrosis
NCT03654248	Not specified	COMPLETED	Let’s Get Organized in Adult Psychiatric/habilitation Care
NCT03659279	Not specified	COMPLETED	Let’s Get Organized Feasibility Study
NCT03722615	Not specified	COMPLETED	Epidemiology of Congenital Cytomegalovirus in a High HIV Prevalence Setting, South Africa
NCT03770832	Not specified	ACTIVE_NOT_RECRUITING	Wearable Sensors and Video Recordings to Monitor Motor Development
NCT03830879	Not specified	RECRUITING	Shenzhen Birth Cohort Study
NCT03835689	Not specified	COMPLETED	Strongest FamiliesTM Neurodevelopmental
NCT03882788	Not specified	COMPLETED	The Effect of Anesthesia on Neurodevelopmental Outcome (NDO)
NCT03922087	Not specified	COMPLETED	No-worry Baby Project
NCT03977259	Not specified	ACTIVE_NOT_RECRUITING	Targeting Human Milk Fortification to Improve Preterm Infant Growth and Brain Development
NCT04043572	Not specified	UNKNOWN	The Biomarkers of Neurological Disease in Utero Study
NCT04096430	Not specified	RECRUITING	Evaluation of Effectiveness of Child-oriented Goal-setting in Paediatric Rehabilitation (the ENGAGE Approach)
NCT04108273	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children